Skip to content
January 27, 2021
The Saint
The Saint

The Saint

The Independent voice of the St Andrews community since 1997.

The Saint Newspaper Logo

  • News
  • Features
  • Viewpoint
  • Culture
  • Money
  • Illustrations
  • Events
  • Sport
  • About
    • Editorial Team
    • Getting involved
    • Resources and Policy

Syringe by Olivia Hendren

News 

University of St Andrews form partnership with biotech start-up ILC Therapeutics

June 29, 2020September 5, 2020 Natalie Pereira Catherine Adamson, Coronavirus, The University of St Andrews

The University of St Andrews is partnering with biotechnology firm, ILC Therapeutics in researching a drug for Covid-19 clinical trials. Dr Catherine Adamson from the School of Biology will be working with the company in order to research how the drug Alfacyte could prevent Acute Respiratory Distress Syndrome (ARDS).

The University of St Andrews is partnering with biotechnology firm, ILC Therapeutics in researching a drug for Covid-19 clinical trials.

Dr Catherine Adamson from the School of Biology will be working with the company in order to research how the drug Alfacyte could prevent Acute Respiratory Distress Syndrome (ARDS). The prevention of ARDS is believed to reduce the need of ventilators for patients as well as averting short-term and long-term damage to the lungs.

Speaking of the new partnership, ILC Therapeutics Founder and Chief Scientific Officer, Professor William Stimson said, “We are delighted to be working with the University of St Andrews to develop our research and work as quickly as possible to bring this potential treatment option to those who need it.”

He continued, “Dr Adamson’s work in the field of virology is highly respected, and to have her backing in our research for Alfacyte is invaluable as we progress towards eventual clinical trials.”

Dr Adamson is an expert in virology and the development of antiviral drugs, having worked in the US National Institutes of Health (NIH) HIV Drug Resistance Program.

Dr Adamson said, “I welcome the opportunity to work with ILC Therapeutics to carry out further research into the part interferons play in the innate immune system’s ability to fight COVID-19. By exploring this in more detail, we can hopefully move closer to having viable treatment options in the coming years.”

60

SHARES
facebook Share on Facebook
Twitter Tweet
Follow Follow us
custom Share
custom Share
custom Share
custom Share
custom Share
  • ← Doubters to Believers – Klopp’s Transformation of Liverpool
  • How Students Can Prosper This Summer →

You May Also Like

Fife Councillor initiates study into pedestrianising Market Street

November 8, 2018November 7, 2018 Natalie Pereira 0

John Burnet residents in “sofa protest”

November 26, 2016November 26, 2016 News 2

Applications open for environment award

September 17, 2015September 16, 2015 News 0
Online Issue 4: Thursday 19 November
Editor's Picks Editors Choice News 

Online Issue 4: Thursday 19 November

November 19, 2020November 19, 2020 Editor

Read the fourth online issue of The Saint. In light of the recent work from home orders and increasing COVID cases, for the short term, we will be collating our typical print releases in an online optimised form.

  • Home
  • About
  • Contact
  • Editorial Team
  • Getting Involved
  • In Print
  • Disclaimer
  • Advertising
Copyright © 2021 The Saint. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.